Informational only — Not medical advice. Always consult a licensed healthcare provider.

MedBD
বাং
Community data Updated 2 months ago
🌐 বাংলায় দেখুন

Indications

Chronic Obstructive Pulmonary Disease Bronchitis

Rofusis is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor. By selectively inhibiting the PDE4 isoenzyme, it exerts potential anti-inflammatory and antimodulatory effects within the pulmonary system. It is thought that the resulting rise in intracellular cyclic AMP levels is responsible for Roflumilast's therapeutic actions.

Pregnancy & Breastfeeding

Pregnancy: There isn't much data yet on using Roflumilast during pregnancy. Animal studies have shown effects on reproduction, and the drug has been shown to cross the placenta in pregnant rats. For this reason, Roflumilast is not recommended for pregnant women or for women who could become pregnant and are not using contraception.

Breastfeeding: In animal studies, Roflumilast and its breakdown products have been found in milk, so a risk to a nursing infant cannot be ruled out. Roflumilast should not be used while breastfeeding.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Adult dose: The recommended dose is one tablet of 500 micrograms Roflumilast, taken once daily. It may need to be taken for several weeks before its full effect is felt, and clinical trials have followed its use for up to one year. For elderly patients aged 65 years and older, no dose adjustment is necessary. Patients with renal impairment likewise need no dose adjustment. Patients with mild hepatic impairment, classified as Child Pugh A, have limited clinical data available, so Roflumilast should be used with caution in these cases and a dose adjustment cannot currently be recommended. Patients with moderate or severe hepatic impairment, classified as Child Pugh B or C, must not take Roflumilast. Roflumilast has no relevant use in the pediatric population under 18 years of age. The tablet should be swallowed with water at the same time every day, and it can be taken with or without food.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.